SmartMed Technologies said in a video conference that they are working day and night with a massive research effort in a bid to try and combat the COVID-19 virus and that they are working hand-in-hand with the Chinese based company in attempting to develop a vaccine.

SmartMed Technologies’ Vice President of Research & Development, Ms. Ji-hye Yeong commented on the team up with the Chinese biotech firm saying “Our role in the project will be to provide research and trials for use of the vaccine. Our aim is to increase the body's immune response to the relevant threat and we want to do this as quickly and as safely as possible.”

“This is not our first collaboration between the two companies. We strongly believe in diversification and different ideas and strategies. With all these tools, we are in a positive mood that together, we can develop a vaccine to combat the COVID-19 outbreak and save many lives,” added Ji-hye Yeong, Vice President of Research & Development for SmartMed Technologies.

About Us - SmartMed Technologies

SmartMed Technologies is a pioneering bioinformatics medical research and development company focused on delivering innovative medical products through artificial intelligence technology to combat prevalent, rare and emerging diseases.

Based in Seoul, our team collects and analyzes big data, utilizing artificial intelligence to gain insight into complex diseases such as leukemia and different cancers. Our approach centers on genome integration with high-performance computers and deep artificial intelligence learning.

With our advanced technology, we have been able to cut costs arising from industry trial-and-error procedures; with the integration of supercomputers into our work, we are able to run more comprehensive simulations, better target proteins, discover new drug compounds for a multitude of diseases, and generally increase our capacity for successful drug development.

With international recognition for our research and projects, some in collaboration with world-renowned institutions, we consistently aim to develop our understanding in the medical field through artificial intelligence and advanced clinical trials.